Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
New England Journal of Medicine2013Vol. 369(22), pp. 2083–2092
Citations Over TimeTop 1% of 2013 papers
Scott M. Hammer, Magdalena E. Sobieszczyk, Holly Janes, Shelly Karuna, Mark J. Mulligan, Doug Grove, Beryl A. Koblin, Susan Buchbinder, Michael C. Keefer, Georgia D. Tomaras, Nicole Frahm, John Hural, Chuka Anude, Barney S. Graham, Mary E. Enama, Elizabeth M. Adams, Edwin DeJesus, Richard Novák, Ian Frank, Carter Bentley, Shelly Ramirez, Rong Fu, Richard A. Koup, John R. Mascola, Gary J. Nabel, David C. Montefiori, James G. Kublin, M. Juliana McElrath, Lawrence Corey, Peter B. Gilbert
Abstract
The DNA/rAd5 vaccine regimen did not reduce either the rate of HIV-1 acquisition or the viral-load set point in the population studied. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT00865566.).
Related Papers
- → V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers(2019)17 cited
- Predictors of Willingness of Participate in HIV Vaccine Trials among(2014)
- Construction of the eukaryotic multivalent DNA vaccine SjGST-FABP of Schistosoma japonicum Chinese strain and its immunoprotection in mice(2007)
- Observations on the immune protection induced by the recombinant signal protein 14-3-3 DNA of Schistosoma japonicum(2004)
- 日本血吸虫ONA多价疫苗SjGST-FABP/pcZDNA3的构建及其保护性免疫研究(2007)